Dong-A Socio Holdings

With the global market for obesity expanding rapidly, South Korean newcomer MetaVia is aiming to become a differentiated player in the next wave of cardiometabolic drug development. Despite potential

MetaVia released new data on 22 April from a Phase I trial of its dual oxyntomodulin analog agonist DA-1726 that it claims might position the drug with a best-in-class safety/tolerability and efficacy

The fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical r

2024 was an eventful year for the South Korean biopharma industry with the emergence of several key themes that look set to carry over into the new year. The sector is facing a new growth chapter fuel